Precision Psychiatry Market Overview
The Precision Psychiatry Market is expanding as demand grows for personalized mental healthcare, data-driven diagnosis, and individualized treatment strategies. Increasing prevalence of mental health disorders, advances in genomic medicine and neuroimaging, growing adoption of artificial intelligence, expanding telepsychiatry services, and rising awareness of precision medicine are supporting market growth.
According to the WiseGuyReports market report published in April 2026, the global Precision Psychiatry Market was valued at USD 4.4 Billion in 2024 and is projected to grow from USD 4.7 Billion in 2025 to USD 10.0 Billion by 2035, registering a CAGR of 7.8% during 2026–2035. North America led the market with a value of USD 2.0 Billion in 2024 and is projected to reach USD 4.3 Billion by 2035. Neuroimaging is expected to dominate the therapeutic approach segment, reaching USD 2.5 Billion by 2035, while Genetic Testing is projected to reach USD 3.0 Billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=652959
Key players driving innovation and competitiveness in the Precision Psychiatry Market include:
Eli Lilly and Company
AstraZeneca
Acadia Pharmaceuticals
GSK
IntraCellular Therapies
H. Lundbeck A/S
Bristol Myers Squibb
Merck & Co
Novartis AG
AbbVie
NantKwest
Johnson and Johnson
Otsuka Pharmaceutical
Neurocrine Biosciences
Pfizer Inc
Sage Therapeutics
The market is being shaped by the increasing prevalence of mental health disorders and the growing demand for personalized treatment approaches. Artificial intelligence and machine learning are being integrated into diagnostics and treatment planning, while genomic medicine, pharmacogenomic testing, neuroimaging, and biomarker analysis are helping clinicians develop more individualized care strategies. Digital platforms and telepsychiatry are also expanding access to precision mental healthcare.
The Precision Psychiatry Market can be segmented by Therapeutic Approach into Genetic Testing, Neuroimaging, Pharmacogenomic Testing, and Biomarker Analysis. By Disorder Type, it includes Depression, Anxiety Disorders, Bipolar Disorder, and Schizophrenia. By Patient Demographics, it covers Children, Adults, and Elderly. By Distribution Channel, it includes Hospitals, Clinics, and Homecare. Regionally, the market covers North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
The growing need for individualized psychiatric care is creating opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, diagnostic companies, and digital-health developers. AI-powered diagnostics, pharmacogenomic testing, biomarker-based treatment selection, advanced neuroimaging, telepsychiatry platforms, wearable monitoring, and collaborations between healthcare and technology companies can support market differentiation and future growth.
Recent Developments and Market Trends:
Artificial intelligence and machine learning are increasingly being applied to psychiatric diagnostics and treatment planning, supporting more personalized patient assessments.
Neuroimaging is expected to become the leading therapeutic approach, reaching USD 2.5 Billion by 2035 as advanced brain imaging supports improved diagnosis and treatment personalization.
Genetic Testing is projected to reach USD 3.0 Billion by 2035, reflecting growing interest in genetic factors associated with psychiatric disorders.
Pharmacogenomic Testing is gaining momentum as clinicians seek to understand how individual patients may respond to different psychiatric medications and reduce trial-and-error treatment.
Biomarker Analysis is advancing as researchers identify biological indicators that can help refine psychiatric treatment strategies.
Digital mental-health platforms are expanding, combining therapy, medication management, and continuous monitoring to provide more integrated patient care.
Telepsychiatry is supporting broader access to personalized mental-health services, particularly for patients in remote and underserved areas.
Wearable technologies are increasingly being explored for real-time mental-health monitoring, generating patient data that can support individualized treatment decisions.
North America is expected to maintain market leadership, supported by advanced healthcare infrastructure, strong investment in mental-health technologies, and adoption of precision medicine.
Asia Pacific is emerging as an important growth region due to rising mental-health awareness, increasing healthcare investment, and improving access to precision healthcare technologies.
Reasons to Buy the Report:
Provides comprehensive insights into the Precision Psychiatry Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across genetic testing, neuroimaging, pharmacogenomic testing, and biomarker analysis.
Offers detailed segmentation analysis across therapeutic approach, disorder type, patient demographics, distribution channel, and geographic markets.
Includes competitive intelligence covering leading pharmaceutical, biotechnology, healthcare, and digital-health companies.
Supports informed decisions using market forecasts, mental-health trends, AI adoption, genomic medicine advancements, telepsychiatry expansion, and regional opportunities.
Future Outlook:
The future of the Precision Psychiatry Market will be shaped by increasing mental-health awareness, rising demand for personalized treatment, advances in genomic medicine, AI and machine learning integration, improved neuroimaging, and expanding telepsychiatry services. Neuroimaging should remain a major therapeutic approach, with its market value projected to reach USD 2.5 Billion by 2035, while Genetic Testing is projected to reach USD 3.0 Billion. North America is expected to retain its leadership position, with the regional market projected to grow from USD 2.0 Billion in 2024 to USD 4.3 Billion by 2035. Europe is projected to reach USD 3.2 Billion by 2035, while Asia Pacific is expected to reach USD 1.7 Billion. Integrated digital platforms, biomarker analysis, pharmacogenomic testing, and AI-enabled treatment personalization will create additional opportunities across the market. The global Precision Psychiatry Market is projected to reach USD 10.0 Billion by 2035 at a CAGR of 7.8%.
➤➤Explore Our Latest Related Reports:
